Stress and depression are linked to inhibition of plasticity in preclinical models while activation of neurotrophic cascades in the hippocampus and prefrontal cortex appears necessary and sufficient for efficacy across antidepressant treatment modalities. These treatments appear to specifically target homeostatic synaptic plasticity mechanisms. Yet, the implications of pharmacological neurotrophic stimulation in mammals remain unknown. How do neurotrophic changes at the lowest levels (molecular, cellular) alter function at the highest levels (psychology, cognition)? Our ability to measure plasticity in humans opens the door to answering this question. Here, we discuss promising approaches for measuring markers of neurotrophic stimulation in humans.
Ketamine and psychedelics induce rapid neurotrophic activation, making them ideal candidates for this research. Moreover, the recent resurgence of enthusiasm for psychedelic drugs as treatments for psychiatric disorders increases the importance of demonstrating neurobiological mechanisms of therapeutic efficacy, as well as safety, tolerability, and dosing of these treatments in humans.
The synaptic vesicle glycoprotein 2A (SV2A) localizes to secretory vesicles in neurons and is a reasonable biomarker of synaptic density. SV2A can be quantified in vivo using the positron emission tomography (PET)-based radiotracer 11C-UCB-J [1]. SV2A radiolabeling is reduced in individuals with severe depression and increased in the hippocampus and prefrontal cortex one week after exposure to psilocybin in pigs. Recently, mixed results were seen with this tracer 24 h after ketamine [2]. Other PET-based measures, such as aerobic glycolysis, may provide complementary inroads to studying drug-induced LTP and plasticity. However, risks associated with radiation exposure, as well as cost and limited accessibility may limit clinical utility of PET.
Transcranial Magnetic Stimulation (TMS) offers a lower-cost, non-invasive alternative for assessing drug-induced changes in excitability and neuroplasticity in humans. TMS over motor cortex reduces motor thresholds following sub-anesthetic ketamine [3]. This increased excitability is likely a precursor to homeostatic plasticity. TMS-electroencephalography provides a more flexible tool to measure excitability in response to psychopharmacological manipulation [4]. More complex learning paradigms, capturing changes in evoked potentials after tetanic stimulation, have been proposed to measure rate of activity-dependent synaptic plasticity or Hebbian learning (sometimes termed meta-plasticity). However, these tools require further validation.
Resting state functional MRI (rsfMRI) is a non-invasive method for visualizing neurobiological effects of rapid antidepressants with high spatial fidelity. We recently showed that reduced connectivity between emotional brain areas and the default mode network is a marker of the antidepressant response to subanesthetic ketamine [5]. The precision functional mapping (PFM) strategy strengthens rsfMRI by controlling for individual variability, further increasing reliability and specificity. A recent study suggested that PFM may provide a biomarker of homeostatic plasticity (“plasticity pulses”) [6], offering an additional window into population- and circuit-level effects of plasticity-inducing drugs.
Mechanistic studies of classic antidepressants are challenged by the fact that their neurotrophic effects take weeks or months to manifest, whereas the neurotrophic and antidepressant effects of ketamine and psychedelics are rapid. Quantifying the neurotrophic effects of rapid antidepressants in well-designed clinical trials may thus be key to improving treatments, as well as for guiding routine clinical care.
References
Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin S, Chen M-K, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8:348ra96–348ra96.
Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry. 2022. 15 February 2022. https://doi.org/10.1038/s41380-022-01465-2.
Di Lazzaro V, Oliviero A, Profice P, Pennisi MA, Pilato F, Zito G, et al. Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. J Physiol. 2003;547:485–96.
Tremblay S, Rogasch NC, Premoli I, Blumberger DM, Casarotto S, Chen R, et al. Clinical utility and prospective of TMS–EEG. Clin Neurophysiol. 2019;130:802–44.
Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, et al. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology. 2021;238:1157–69.
Newbold DJ, Laumann TO, Hoyt CR, Hampton JM, Montez DF, Raut RV, et al. Plasticity and Spontaneous Activity Pulses in Disused Human Brain Circuits. Neuron. 2020;107:580–89.e6.
Funding
This work was supported by the Taylor Family Institute Fund for Innovative Psychiatric Research GF0010787, NIMH Research Education Grant R25 MH112473, National Center for Advancing Translational Sciences grant UL1 TR002345 (ICTS Award #5157), and McDonnell Center for Systems Neuroscience Award #202002165.
Author information
Authors and Affiliations
Contributions
JSS and GEN contributed to writing of this manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Siegel, J.S., Nicol, G.E. Plasticity markers in the human brain associated with rapid antidepressants. Neuropsychopharmacol. 48, 223–224 (2023). https://doi.org/10.1038/s41386-022-01400-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-022-01400-7
This article is cited by
-
Psilocybin desynchronizes the human brain
Nature (2024)